

ASX ANNOUNCEMENT

Actinogen at SACHS Forum and JP Morgan week

- Actinogen to present at the 3rd Annual SACHS Neuroscience Innovation Forum and participate in partnering meetings during JPM Week in San Francisco, USA
- Excellent opportunity for the Company to present the breakthrough XanaHES results and Xanamem's expanded dataset on a global stage
- Xanamem has been demonstrated to be an efficacious, brain penetrant and appropriately safe oral drug, with clinical results in line with its intended mechanism of action
- Actinogen will engage with investors, potential strategic partners and the scientific and medical communities during the JPM week

Sydney, 8 January 2020. Actinogen Medical ASX: ACW ('ACW' or 'the Company') will present at the 3rd Annual SACHS Neuroscience Innovation Forum and participate in numerous partnering meetings during JPM week in San Francisco, USA in January 2020.

The SACHS Forum and JPM Week provides the Company with an excellent opportunity to update the pharmaceutical industry and major global investors interested in Neuroscience on the compelling results achieved with XanaHES, and the expanded Xanamem dataset generated during 2019.

Latest Xanamem developments that will be discussed at both events include:

- Breakthrough XanaHES results demonstrating a robust and statistically significant effect on improving cognition in healthy elderly patients taking 20mg Xanamem daily
- Target Occupancy results confirming that Xanamem works as designed to penetrate the brain in concentrations that adequately inhibit the activity of the 11 β -HSD1 enzyme
- Strong safety profile and cortisol inhibition demonstrated in human trials with 10mg and 20mg Xanamem

Following the Forum, Actinogen will participate in multiple partnering meetings during the week, which is concurrent with the 38th Annual J.P. Morgan Healthcare Conference. This preeminent global investment and business development conference attracts numerous international pharmaceutical leaders and investors.

Attached is the latest investor presentation that will be utilised in the SACHS presentation and discussed during the Company's numerous partnering meetings.

If you are interested in a meeting with Actinogen in San Francisco from 13 to 16 January 2020, please contact the Company using the details below.

ENDS

Actinogen Medical

Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au

 @BillKetelbey

Investor and Media Enquiries

Arthur Chan
WE Communications
P: +61 2 9237 2805
E: arthurc@we-worldwide.com

Announcement authorised by the Board of Directors of Actinogen Medical

About SACHS Neuroscience Innovation Forum

The 3rd Annual Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology is to take place at the Marines' Memorial Club, San Francisco on the 12 January 2020. The program will cover BioPartnering for CNS, with industry keynotes and panels on AD, PD, Neuropsychiatry and Pain Management. The Forum brings together biotech companies focused on central nervous system conditions with partnering executives from pharm, biotech and medtech companies and analysts from investment banks and funds.

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotechnology company developing novel therapies for cognitive impairment associated with chronic neurological and metabolic diseases. The company is currently developing its lead compound Xanamem as a promising new therapy for Alzheimer's disease and cognitive impairment associated with schizophrenia and mood disorders. The cognitive dysfunction associated with these conditions is significantly debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other therapies for Alzheimer's disease. It works by blocking the excess production of intracellular cortisol – the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. There is a strong association between persistent stress and the production of excess cortisol that leads to changes in the brain, affecting memory. The 11β-HSD1 enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain associated with cognitive impairment in neurological diseases, including Alzheimer's disease, schizophrenia and the mood disorders. The Company's XanaHES Phase I trial exploring the safety and tolerability of Xanamem™ 20mg once daily in healthy elderly volunteers, showed that the drug exhibited a good safety profile with no treatment-related serious adverse events. Additionally, the trial demonstrated that Xanamem™ produced a statistically significant improvement in cognition, which, along with other data recently generated, confirms the underlying mechanism of action of Xanamem.

The Company plans to initiate Phase II studies of Xanamem in various disease areas in 2020, including in Alzheimer's disease, and in cognitive impairment associated with schizophrenia, mood disorders and diabetes.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.